Search results
Author(s):
Giuseppe Rosano
,
Stephen J Greene
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Giuseppe Rosano and Dr Stephen Greene discuss the implementation of guideline-directed medical therapy (GDMT) in heart failure and strategies to overcome clinical inertia.
View more
Author(s):
Added:
1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the…
View more
Author(s):
Andrew JS Coats
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more
Ankur Kalra
Research Area(s) / Expertise:
Author
Isabella Tan
Job title: Research Fellow
Author
Author(s):
Milind Y Desai
Added:
1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed the late-breaking science sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30th August to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View…
View more
Author(s):
Stephen J Greene
Added:
1 year ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
David Quek
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Reshaping Early Identification and Diagnosis of HF
Video Series